Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma Abstract #48

Introduction: Medullary thyroid carcinoma (MTC) accounts for about 5-10% of all thyroid cancers, and while disease localized to the thyroid can be cured by surgery, there is no effective treatment for disseminated MTC. Constitutive activation of the RET proto-oncogene is implicated in familial and a proportion of sporadic cases, and up-regulates the AKT/PI3-kinase/mTOR signal transduction pathway. Recent studies have shown that the inhibitor of mTOR, everolimus (RAD001, Novartis, Basel), can inhibit the proliferation of the TT cell line and human MTC tumor cells in vitro. Clinically, everolimus has been shown to attenuate the progression of some gastrointestinal neuroendocrine tumors, but its clinical use in MTC has not yet been evaluated.
Aim(s): An early progress report on the use of RAD001 in the clinical treatment of a patient with progressive MTC.
Materials and methods: A patient with metastatic MTC received RAD001 (with institutional approval for compassionate use) and the effects evaluated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maralyn R Druce

To read results and conclusion, please login ...

Further abstracts you may be interested in

#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)
Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maria Gueorguiev
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#160 The role of T-type calcium channels in medullary thyroid carcinoma (MTC): T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a human MTC cell line
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5-10% of thyroid cancers. In the case of tumors limited to the thyroid gland, the prognosis is generally favorable, whereas 5-year survival averages only 40% in patients with metastatic disease. In these patients, conventional chemotherapy only occasionally leads to a complete response and partial responses are observed in less than 30% of the cases. Therefore, intense efforts are currently directed toward the identification of new druggable targets for the treatment of this devastating disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Rosario Pivonello
#266 Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that everolimus, an mTOR inhibitor, has a potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Chiara Zatelli
#333 Sporadic Hypercalcitoninemia: Thyroid Medullary carcinoma, Autoimmune Thyroiditis or GLP-1 Agonists’ Effect?
Introduction: Glucagon-like peptide 1 (GLP-1) receptor agonists’ stimulated C-cell hyperplasia and tumors in rodents, but not in humans. Calcitonin also increased in autoimmune thyroid disease.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Raluca A. Trifanescu